Current Liabilities
Deferred Revenue
Thermo Fisher Scientific Deferred Revenue increased by 8.0% to $2.93B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.2%, from $2.87B to $2.93B. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows an upward trend with a 16.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase is generally positive, signaling strong future demand and cash collection, while a decrease indicates the fulfillment of obligations.
Detailed definition
This represents payments received from customers for goods or services that have not yet been delivered or performed. It...
Peer comparison
Common in subscription and long-term contract businesses; highly indicative of future revenue visibility.
Metric ID:
deferred_revenue_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.47B | $1.44B | $2.66B | $2.87B | $2.72B | $2.57B | $2.60B | $2.66B | $2.59B | $2.55B | $2.69B | $2.63B | $2.59B | $2.66B | $2.85B | $2.87B | $2.81B | $2.85B | $2.71B | $2.93B |
| QoQ Change | — | -1.9% | +84.1% | +8.1% | -5.2% | -5.7% | +1.3% | +2.3% | -2.7% | -1.7% | +5.6% | -2.1% | -1.6% | +2.8% | +7.1% | +0.5% | -2.1% | +1.7% | -5.0% | +8.0% |
| YoY Change | — | — | — | — | +85.2% | +78.0% | -2.0% | -7.3% | -4.8% | -0.8% | +3.4% | -1.1% | +0.0% | +4.6% | +6.1% | +8.9% | +8.3% | +7.1% | -5.0% | +2.2% |
Range$1.44B – $2.93B
CAGR+15.6%
Avg YoY Growth+11.4%
Median YoY Growth+2.8%
Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's deferred revenue?
- Thermo Fisher Scientific (TMO) reported deferred revenue of $2.93B in Q1 2026.
- How has Thermo Fisher Scientific's deferred revenue changed year-over-year?
- Thermo Fisher Scientific's deferred revenue increased by 2.2% year-over-year, from $2.87B to $2.93B.
- What is the long-term trend for Thermo Fisher Scientific's deferred revenue?
- Over 5 years (2020 to 2025), Thermo Fisher Scientific's deferred revenue has grown at a 16.3% compound annual growth rate (CAGR), from $1.27B to $2.71B.
- What does deferred revenue mean?
- Cash received from customers for work that has not yet been completed.